Qlucore (QCORE) Q3 2026 earnings summary

Executive summary

• Net sales for Q3 were SEK 2,190k, down 32% year-over-year; nine-month sales fell 29% to SEK 4,793k.

• Adjusted EBITDA improved to SEK -3,088k in Q3 from SEK -5,313k last year; nine-month adjusted EBITDA was SEK -10,357k.

• Net result for Q3 was SEK -3,311k, a smaller loss than SEK -5,118k last year; nine-month net loss widened to SEK -33,142k.

• New product Qlucore Omics Explorer 3.11 launched with expanded protein data support.

• Two major Nordic hospitals now use the diagnostic solution for childhood leukaemia.

Financial highlights

• Q3 net sales: SEK 2,190k (down from SEK 3,217k); nine-month net sales: SEK 4,793k (down from SEK 6,747k).

• Q3 adjusted EBITDA: SEK -3,088k (improved from SEK -5,313k); nine-month adjusted EBITDA: SEK -10,357k (improved from SEK -21,998k).

• Q3 net result: SEK -3,311k (improved from SEK -5,118k); nine-month net result: SEK -33,142k (worse than SEK -18,597k).

• Cash flow from operating activities in Q3: SEK -2,555k (improved from SEK -5,542k); nine-month cash flow: SEK -5,421k (improved from SEK -9,207k).

• Net cash flow for nine months: SEK 5,574k (improved from SEK -16,978k), mainly due to a rights issue.

• Cash and cash equivalents at period end: SEK 10,903k.

Outlook and guidance

• No market outlook or earnings forecast is provided.